市場調査レポート
商品コード
1668080

先進治療医薬品CDMO市場- 世界の産業規模、シェア、動向、機会、予測、製品別、フェーズ別、適応症別、地域別、競合別セグメント、2020～2030年

Advanced Therapy Medicinal Products CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Phase, By Indication, By Region and Competition, 2020-2030F
表紙：先進治療医薬品CDMO市場- 世界の産業規模、シェア、動向、機会、予測、製品別、フェーズ別、適応症別、地域別、競合別セグメント、2020～2030年

出版日
ページ情報
英文 180 Pages
納期
2～3営業日
カスタマイズ可能
先進治療医薬品CDMO市場- 世界の産業規模、シェア、動向、機会、予測、製品別、フェーズ別、適応症別、地域別、競合別セグメント、2020～2030年
出版日: 2025年02月28日
発行: TechSci Research
ページ情報: 英文 180 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

先進治療医薬品CDMOの世界市場規模は2024年に51億2,000万米ドルで、予測期間中のCAGRは9.54%で2030年には88億7,000万米ドルに達すると予測されています。

先進治療医薬品CDMOの世界市場は、製薬とバイオテクノロジー産業の中でもダイナミックで急速に発展しているセグメントです。この市場には、遺伝子治療、細胞治療、組織工学製品などを含む先進治療医薬品（ATMP）の開発・製造に特化したサービスを提供する組織が含まれます。

市場概要
予測期間 2026～2030年
市場規模：2024年 51億2,000万米ドル
市場規模：2030年 88億7,000万米ドル
CAGR：2025～2030年 9.54%
急成長セグメント 腫瘍学
最大市場 北米

市場促進要因

先進治療医薬品の普及

主要市場課題

高コスト

主要市場動向

コラボレーションとパートナーシップの増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の先進治療医薬品CDMO市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 製品別（遺伝子治療、細胞治療、組織工学、その他）
    • フェーズ別（フェーズ I、フェーズ II、フェーズ III、フェーズ IV）
    • 適応症別（腫瘍学、心臓病学、中枢神経系、筋骨格系、感染症、免疫学と炎症、その他）、
    • 地域別
    • 企業別（2024年）
  • 市場マップ

第6章 北米の先進治療医薬品CDMO市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の先進治療医薬品CDMO市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋の先進治療医薬品CDMO市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の先進治療医薬品CDMO市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの先進治療医薬品CDMO市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収（該当する場合）
  • 製品の発売（該当する場合）

第13章 ポーターのファイブフォース分析

  • 産業内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Celonic AG
  • Rentschler Biopharma SE
  • Catalent, Inc.
  • Lonza Group AG
  • WuXi Advanced Therapies
  • Minaris Regenerative Medicine, LLC
  • Pluri BIoTech Ltd.
  • REPROCELL USA Inc.
  • BioPhorum Operations Group
  • Cellares Corporation

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 18839

Global Advanced Therapy Medicinal Products CDMO Market was valued at USD 5.12 Billion in 2024 and is expected to reach USD 8.87 Billion by 2030 with a CAGR of 9.54% during the forecast period. The Global Advanced Therapy Medicinal Products CDMO Market is a dynamic and rapidly evolving sector within the pharmaceutical and biotechnology industries. This market encompasses organizations that provide specialized services for the development and manufacturing of advanced therapy medicinal products (ATMPs), which include gene therapies, cell therapies, and tissue-engineered products.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 5.12 Billion
Market Size 2030USD 8.87 Billion
CAGR 2025-20309.54%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key Market Drivers

Proliferation of Advanced Therapies

The healthcare landscape is witnessing a revolution as advanced therapies, including gene therapies, cell therapies, and tissue-engineered products, emerge as groundbreaking treatments for previously incurable diseases. This paradigm shift in medicine is driving the demand for specialized services provided by Contract Development and Manufacturing Organizations (CDMOs).

The advent of advanced therapies has expanded therapeutic horizons, offering new hope to patients suffering from rare and debilitating conditions. These therapies target the root causes of diseases at the genetic and cellular levels, promising higher efficacy and fewer side effects compared to traditional treatments. As more conditions become treatable through advanced therapies, the demand for CDMO services to develop and manufacture these products increases.

Pharmaceutical companies, biotechnology firms, and academic institutions are investing heavily in advanced therapy research and development. This surge in investment translates into a growing pipeline of potential therapies. CDMOs are integral to this process, providing the expertise and infrastructure needed to advance these therapies from the laboratory to clinical trials and eventual commercialization.

The development and manufacturing of advanced therapies come with complex regulatory challenges. Regulatory bodies like the FDA and EMA have stringent requirements to ensure the safety and efficacy of these novel treatments. CDMOs specializing in advanced therapies possess the regulatory expertise to help clients navigate this intricate landscape, ensuring compliance throughout the product lifecycle. This support streamlines the regulatory approval process, accelerating market entry.

Key Market Challenges

High Costs

The development and manufacturing of advanced therapies, such as ATMPs (Advanced Therapy Medicinal Products), are inherently resource-intensive. These therapies require significant investment in research and development, with cutting-edge technology and highly specialized expertise necessary for their creation. The costs associated with preclinical and clinical trials, regulatory approvals, and the production of these therapies can often be prohibitively high, which poses a challenge for Contract Development and Manufacturing Organizations (CDMOs) involved in the production process. Furthermore, the advanced nature of these products demands high-quality standards, specialized facilities, and skilled personnel to ensure safety, efficacy, and compliance with stringent regulations. CDMOs must find innovative ways to streamline production processes, optimize resource allocation, and implement cost-control strategies without compromising the quality of the therapies being developed. Balancing cost efficiency while meeting the demands for high-end manufacturing processes is a critical challenge in the ATMP sector, and finding sustainable solutions is key to ensuring the long-term success of these products.

Key Market Trends

Increased Collaboration and Partnerships

Collaboration is increasingly becoming a critical driver of innovation within the Advanced Therapy Medicinal Product (ATMP) sector. As the complexity and scope of these therapies continue to grow, Contract Development and Manufacturing Organizations (CDMOs) are recognizing the importance of strategic partnerships with pharmaceutical companies, biotech startups, and academic institutions. These alliances allow stakeholders to pool resources, share knowledge, and co-develop cutting-edge therapies that may otherwise be challenging to create independently. In February 2022, Recipharm AB successfully finalized its acquisition of Vibalogics. Through this arrangement, Recipharm is set to gain valuable expertise in biologics, harnessing Vibalogics' capabilities in areas such as viral vaccines, oncolytic viruses, and gene treatments using viral vectors. This strategic move is expected to provide Recipharm with a substantial diversification of its offerings across various technologies and modalities.

Key Market Players

  • Celonic AG
  • Rentschler Biopharma SE
  • Catalent, Inc.
  • Lonza Group AG
  • WuXi Advanced Therapies
  • Minaris Regenerative Medicine, LLC
  • Pluri Biotech Ltd.
  • REPROCELL USA Inc.
  • BioPhorum Operations Group
  • Cellares Corporation

Report Scope:

In this report, the Global Advanced Therapy Medicinal Products CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Advanced Therapy Medicinal Products CDMO Market, By Product:

  • Gene Therapy
  • Cell Therapy
  • Tissue Engineered
  • Others

Advanced Therapy Medicinal Products CDMO Market, By Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Advanced Therapy Medicinal Products CDMO Market, By Indication:

  • Oncology
  • Cardiology
  • Central Nervous System
  • Musculoskeletal
  • Infectious disease
  • Immunology & inflammation
  • Others

Advanced Therapy Medicinal Products CDMO Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Advanced Therapy Medicinal Products CDMO Market.

Available Customizations:

Global Advanced Therapy Medicinal Products CDMO market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Advanced Therapy Medicinal Products CDMO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others)
    • 5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
    • 5.2.3. By Indication (Oncology, Cardiology, Central Nervous System, Musculoskeletal, Infectious disease, Immunology & inflammation, Others),
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Advanced Therapy Medicinal Products CDMO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Phase
    • 6.2.3. By Indication
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Advanced Therapy Medicinal Products CDMO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Phase
        • 6.3.1.2.3. By Indication
    • 6.3.2. Canada Advanced Therapy Medicinal Products CDMO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Phase
        • 6.3.2.2.3. By Indication
    • 6.3.3. Mexico Advanced Therapy Medicinal Products CDMO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Phase
        • 6.3.3.2.3. By Indication

7. Europe Advanced Therapy Medicinal Products CDMO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Phase
    • 7.2.3. By Indication
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Advanced Therapy Medicinal Products CDMO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Phase
        • 7.3.1.2.3. By Indication
    • 7.3.2. United Kingdom Advanced Therapy Medicinal Products CDMO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Phase
        • 7.3.2.2.3. By Indication
    • 7.3.3. Italy Advanced Therapy Medicinal Products CDMO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Phase
        • 7.3.3.2.3. By Indication
    • 7.3.4. France Advanced Therapy Medicinal Products CDMO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Phase
        • 7.3.4.2.3. By Indication
    • 7.3.5. Spain Advanced Therapy Medicinal Products CDMO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Phase
        • 7.3.5.2.3. By Indication

8. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Phase
    • 8.2.3. By Indication
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Advanced Therapy Medicinal Products CDMO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Phase
        • 8.3.1.2.3. By Indication
    • 8.3.2. India Advanced Therapy Medicinal Products CDMO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Phase
        • 8.3.2.2.3. By Indication
    • 8.3.3. Japan Advanced Therapy Medicinal Products CDMO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Phase
        • 8.3.3.2.3. By Indication
    • 8.3.4. South Korea Advanced Therapy Medicinal Products CDMO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Phase
        • 8.3.4.2.3. By Indication
    • 8.3.5. Australia Advanced Therapy Medicinal Products CDMO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Phase
        • 8.3.5.2.3. By Indication

9. South America Advanced Therapy Medicinal Products CDMO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Phase
    • 9.2.3. By Indication
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Advanced Therapy Medicinal Products CDMO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Phase
        • 9.3.1.2.3. By Indication
    • 9.3.2. Argentina Advanced Therapy Medicinal Products CDMO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Phase
        • 9.3.2.2.3. By Indication
    • 9.3.3. Colombia Advanced Therapy Medicinal Products CDMO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Phase
        • 9.3.3.2.3. By Indication

10. Middle East and Africa Advanced Therapy Medicinal Products CDMO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Phase
    • 10.2.3. By Indication
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Advanced Therapy Medicinal Products CDMO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Phase
        • 10.3.1.2.3. By Indication
    • 10.3.2. Saudi Arabia Advanced Therapy Medicinal Products CDMO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Phase
        • 10.3.2.2.3. By Indication
    • 10.3.3. UAE Advanced Therapy Medicinal Products CDMO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Phase
        • 10.3.3.2.3. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Celonic AG
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Rentschler Biopharma SE
  • 14.3. Catalent, Inc.
  • 14.4. Lonza Group AG
  • 14.5. WuXi Advanced Therapies
  • 14.6. Minaris Regenerative Medicine, LLC
  • 14.7. Pluri Biotech Ltd.
  • 14.8. REPROCELL USA Inc.
  • 14.9. BioPhorum Operations Group
  • 14.10. Cellares Corporation

15. Strategic Recommendations

16. About Us & Disclaimer